FACTSHEET

About IDT

- IDT, an operating company within Danaher Corporation's (NYSE: DHR) Life Sciences platform, was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Leuven, Belgium; and Singapore.
- IDT leads the industry in the manufacture of custom oligonucleotides for molecular biology applications. IDT has also developed proprietary technologies for genomics applications, such as Next Generation Sequencing, CRISPR genome editing, qPCR, and RNA interference.
- IDT serves more than 130,000 life sciences researchers in more than 100 countries.
- IDT has approximately 1,500 employees worldwide.
- Our recent history includes providing products to diagnostic test manufacturers developing tests for Ebola virus and Zika virus.
- IDT has already shipped synthetic genes for use in the pursuit of coronavirus vaccines, as well as customized oligonucleotide probes and primers that will facilitate more sensitive and accurate detection of COVID-19.

IDT's COVID-19 Response

- On January 28, 2020, IDT announced it was accepting pre-orders from the global public health and research communities for qPCR primers and probes designed to aid researchers in the detection of COVID-19. IDT started fulfilling orders on February 10.
- The primer and probe kits are manufactured in IDT's Coralville, Iowa headquarters. The primer and probe kits are manufactured under ISO 13485:2016 conditions in a suite of cleanrooms designed to prevent synthetic template contamination. The primer and probe kits are formulated to meet CDC's recommended primer-to-probe ratio.

- IDT is manufacturing primer and probe kits that can be used as a component of the CDC testing protocol for which the CDC obtained Emergency Use Authorization (EUA) for the diagnosis and detection of COVID-19.
- The CDC and FDA first contacted IDT on February 25 to discuss its ability to support the CDC EUA testing protocol. IDT shipped primer and probe kits to the CDC the same day for delivery on February 26. On March 2, the FDA included lot#0000500383 as the first lot of primers and probe kits qualified under the CDC's EUA. Subsequently, the CDC has continued to qualify additional lots. Current information on qualified lots is available on the IDT website. (https://www.idtdna.com/pages/landing/coronavirus-research-reagents#media).
- As of April 3, 2020, IDT has produced primer and probe kits sufficient to enable approximately 23 million tests to be conducted in the US pursuant to the CDC EUA testing protocol.
- The CDC EUA testing protocol for the diagnosis and detection of COVID-19 requires special testing equipment and is not a direct to consumer test. IDT's primer and probe kits are made available to the CDC and other qualified institutions who carry out disease diagnosis as a routine matter of their business. These tests require specific equipment and consumable reagents in order to complete the testing.

Media contacts:
Anna Blyth ablyth@apcoworldwide.com
Iris Shaffer ishaffer@apcoworldwide.com